| First Author | Chen WC | Year | 2010 |
| Journal | Blood | Volume | 115 |
| Issue | 23 | Pages | 4778-86 |
| PubMed ID | 20181615 | Mgi Jnum | J:161568 |
| Mgi Id | MGI:4459619 | Doi | 10.1182/blood-2009-12-257386 |
| Citation | Chen WC, et al. (2010) In vivo targeting of B-cell lymphoma with glycan ligands of CD22. Blood 115(23):4778-86 |
| abstractText | Antibody-mediated cell depletion therapy has proven to provide significant clinical benefit in treatment of lymphomas and leukemias, driving the development of improved therapies with novel mechanisms of cell killing. A current clinical target for B-cell lymphoma is CD22, a B-cell-specific member of the sialic acid binding Ig-like lectin (siglec) family that recognizes alpha2-6-linked sialylated glycans as ligands. Here, we describe a novel approach for targeting B lymphoma cells with doxorubicin-loaded liposomal nanoparticles displaying high-affinity glycan ligands of CD22. The targeted liposomes are actively bound and endocytosed by CD22 on B cells, and significantly extend life in a xenograft model of human B-cell lymphoma. Moreover, they bind and kill malignant B cells from peripheral blood samples obtained from patients with hairy cell leukemia, marginal zone lymphoma, and chronic lymphocytic leukemia. The results demonstrate the potential for using a carbohydrate recognition-based approach for efficiently targeting B cells in vivo that can offer improved treatment options for patients with B-cell malignancies. |
